About Lonza
Lonza is a publicly listed company based in Basel (Switzerland) founded in 1897, and was acquired by SBI Mutual Fund in February 2024. CDMO services for pharma, biotech, and specialty ingredients are provided. Lonza has raised $100 thousand across 6 funding rounds from investors including SBI Mutual Fund, European Union and ALSA Ventures. The company has 18,690 employees. Lonza has completed 10 acquisitions, including Capsugel, InterHealth Nutraceuticals and Lonza. Its chief executive, as recorded, is Pierre Alain Ruffieux. Its website lonza.com draws about 297 thousand monthly visits. Lonza offers products and services including Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides.
Company details
Provider of CDMO services to pharma, biotech, and specialty ingredient markets. The company offers a complete range of development and manufacturing services for fine chemicals, advanced intermediates, active pharmaceutical ingredients (APIs), biologics, and functional ingredients. They claim to offer synergies between chemical synthesis and biotechnology to enable the production of tailor-made intermediates and APIs for use as pharmaceuticals, biotherapies, nutraceuticals, and cosmetics. Their proprietary platforms and development technologies such as GS Gene enable them to offer customized biological and chemical manufacturing solutions. In 2022, the company recorded annual revenues of 6.52B and a net profit of 1.27B.
- Headquarters Basel, Switzerland
- Employees 18,690
- Stage Acquired
- SectorsHealthcare
- Website category Heavy Industry and Engineering · Chemical Industry
- Email••••••••
- Website lonza.com
- Social LinkedIn X Facebook
- Acquired by SBI Mutual Fund (Feb 2024)
- Legal Name Lonza Group Ag
- Annual Revenue$8.24 B (USD)19.18as on Dec 31, 2025
- Net Profit-$346.92 M (USD)-143.24as on Dec 31, 2025
- EBITDA$2.56 B (USD)29.58as on Dec 31, 2025
- Total Equity Funding$100K (USD)
in 6 rounds
- Latest Funding Round$100K (USD), Seed
Nov 2023
- InvestorsSBI Mutual Fund
& 4 more
- Employee Count18,690
- Investments & AcquisitionsCapsugel
& 9 more
- Acquired bySBI Mutual Fund
(Feb 2024)
Associated legal entities of Lonza
Lonza is associated with 3 registered companies on The Company Check. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Arch Protection Chemicals Private Limited CIN U74930MH2010FTC207485 | Active | 07 Sep 2010 | Mumbai, Maharashtra | ₹122 Cr | 32 | 3 | View details |
| Lonza India Private Limited CIN U24230HR1999PTC095355 | Active | 25 Jan 1999 | Gurugram, Haryana | ₹0.0 Cr | 12 | 2 | View details |
| Capsugel Healthcare Private Limited CIN U85110HR1982PTC020151 | Active | 13 Dec 1982 | Gurugram, Haryana | ₹341 Cr | 244 | 4 | View details |
Products & Services of Lonza
Lonza offers a comprehensive portfolio of products and services, including Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
End-to-end development and manufacturing for biologics
Services for small molecules and highly potent APIs
Development for cell, gene, and mRNA technologies
Funding Insights of Lonza
Lonza has successfully raised a total of $100K across 6 strategic funding rounds. The most recent funding activity was a Seed round of $100 thousand completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100,000
- Total Rounds 6
- Last Round Seed — $100,000
- First Round $18M
(Nov 2010)
- Investors Count 4
All 6 funding rounds of Lonza with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $100,000 | Seed | – | – | |
| May 2022 | Post-IPO | – | – | ||
| Jan 2019 | $472,154 | Grant | – | – | |
| Oct 2015 | Grant | – | – | ||
| Jan 2015 | Grant | – | – | ||
| Nov 2010 | $18M | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Lonza
Lonza has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SBI Mutual Fund, European Union and ALSA Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in biotechnology companies for novel therapeutics is managed. | alsaventures.com | London, United Kingdom | ||
AI startup acceleration and networking services are offered globally. | upekkha.io | |||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Provides mutual funds management and financial advisory services. | 1987 | sbimf.com | Mumbai, India |
Investor details for Lonza
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Lonza
The boards of the 3 registered companies of Lonza currently have 7 directors; the longest-serving is Sanjay Khatau Asher, appointed in 2012. 53 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjay Khatau Asher DIN 00008221 | Director | 08 May 2012 | 14 yrs 5 mo | Arch Protection Chemicals Private Limited |
| Olivier Gregory Johan Van Hoorebeke DIN 07417572 | Director | 01 Feb 2016 | 10 yrs 8 mo | Capsugel Healthcare Private Limited, Lonza India Private Limited |
| Minal Golecha DIN 09280535 | Director | 07 Sep 2021 | 5 yrs 1 mo | Arch Protection Chemicals Private Limited |
| Sriram Balasubramaniam Iyer DIN 10658592 | Director | 06 Jun 2024 | 2 yrs 4 mo | Lonza India Private Limited |
| Vishesh Sharma DIN 10686779 | Director | 28 Jun 2024 | 2 yrs 4 mo | Capsugel Healthcare Private Limited |
| Aanchal Tomar DIN 10801737 | Director | 08 Oct 2024 | 2 yrs | Capsugel Healthcare Private Limited |
| Ravinder Singh Mann DIN 10971603 | Director | 19 Mar 2025 | 1 yr 7 mo | Arch Protection Chemicals Private Limited |
People of Lonza
145 people are tracked at Lonza (100 in leadership, 45 in team); the tracked headcount is 18,690.
| Name | Role | Group |
|---|---|---|
Pierre Alain Ruffieux | CEO | Leadership |
Myrna Wilson | Senior Sales Director | Leadership |
Katie Higgins | VP Head Of Talent And Organizational Development | Leadership |
Katja Fleischer | Vice President - Head Of Tax | Leadership |
Debbie Walling | Head Of Human Resources | Leadership |
Philippe Deecke | Group Chief Financial Officer | Leadership |
Annie Lim | Head Of Human Resources | Leadership |
Lindsey Toth | Director, Sales | Leadership |
Wolfgang Wienand | CEO | Leadership |
Diane Lever | Senior Vice President, Global Head Of Sales, Lonza Biologics | Leadership |
Marc Glaeser | Global Head HR Coes And M&a | Leadership |
Elise van Andel | VP Head Of HR Operations And Delivery | Leadership |
Courtney Galligan | Senior Director Of Strategy & Operations, Licensing | Leadership |
Julian Mass | Executive Director, Head of Finance Global Operation, Advanced Synthesis Platform | Leadership |
Alexander Umpelev | Vice President, CFO Small Molecules Division At Lonza | Leadership |
Tanja Kiefer | Head Of HR Strategy And Implementation | Leadership |
Ciandra Barber | Head Of Learning | Leadership |
Kati Merriam | Associate Director - Global Commercial Learning And Enablement | Leadership |
Magdalena van Breda | Global Head Of Training And Learning (finance) | Leadership |
Sean Diver | Head Of East Coast Account Management - Biologics Sales | Leadership |
125 more people are available in the full profile.
Complete people profiles for Lonza
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lonza
Lonza is a publicly listed company on the SIX with ticker symbol LONN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Jul 2020
- Listed onSWX: LONN
- Listed entityLonza Group AG
- Exchange sectorHealth technology
- ISINCH0013841017
- Share price483.20 CHF (+0.04% on the day) · 2026-05-11
- Market capitalisation32,915,673,203.00 CHF
- Price to earnings53.8
- EPS (diluted, trailing year)-3.93 CHF
- Dividend yield0.83%
- Volume (last session)24,806
- Analyst consensusStrong buy
Financials of Lonza
Figures of Capsugel Healthcare Private Limited, the primary company behind Lonza, for FY 2025. Revenue was ₹341 Cr (+9% year on year). Net loss was -₹47.42 Cr (-14% margin). EBITDA was -₹24.20 Cr (-7% margin). Revenue has grown at a compounded annual rate of +18% over three years and +24% over five years.
- ₹341 CrRevenue · FY 2025 · +9% YoY
- -₹47.42 CrNet loss · -14% margin
- -₹24.20 CrEBITDA · -7% margin
- ₹629 CrPaid-up capital
- 244Employees (provident fund records)
- +18%Revenue CAGR, 3 years
- +24%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 6.53B CHF | -275.0M CHF | 2.03B CHF |
| 2024 | 5.48B CHF | 636.0M CHF | 1.56B CHF |
| 2023 | 6.72B CHF | 654.0M CHF | 1.48B CHF |
| 2022 | 6.22B CHF | 1.22B CHF | 1.95B CHF |
| 2021 | 5.41B CHF | 2.94B CHF | 1.34B CHF |
Balance sheet, profit and loss, cash flow and ratios of Capsugel Healthcare Private Limited are on its company page.
Detailed financial statements for Lonza
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lonza
Lonza has strategically engaged in corporate development activities, having acquired 10 companies. Notable acquisitions include Capsugel, InterHealth Nutraceuticals and Lonza.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-drug conjugate technology platform is developed for cancer therapies. | synaffix.com | Nijmegen, Netherlands | 2010 | Jun 2023 | $172M | |
Advanced bioreactors and biomaterials are developed for regenerative medicine. | octaneco.com | Kingston, Canada | 2007 | Oct 2018 | •••• | |
Contract micronization services for APIs and HPAPIs are provided. | micromacinazione.com | Lugano, Switzerland | 1970 | Jul 2017 | •••• | |
Contract development and manufacturing for cell therapies are provided. | pharmacell.nl | Maastricht, Netherlands | 2005 | May 2017 | •••• | |
Dosage forms are delivered for preclinical, clinical, and commercial supply. | capsugel.com | Morristown, United States | 1875 | Dec 2016 | $6.2B | |
Nutraceutical and specialty ingredients are researched, developed, and supplied. | interhealthusa.com | Benicia, United States | 1987 | Aug 2016 | $300M | |
Provider of cryopreserved hepatocytes for research purposes | triangleresearchlabs.net | Durham, United States | 2012 | Jun 2016 | •••• | |
Agrochemicals and products for timber treatment | zelam.com | New Plymouth, New Zealand | 1992 | Aug 2015 | •••• | |
Viral vectors for gene therapy applications are manufactured. | vivante-gmp.com | Houston, United States | 2009 | Aug 2010 | •••• | |
Drug research, development, and custom manufacturing services are offered. | modatp.com | Wayne, United States | 2005 | May 2010 | •••• |
Complete acquisition details for Lonza
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lonza
15 dated milestones of Lonza across 127 years, from founding to its latest funding, stage changes and deals.
- Founded Lonza is founded.
- Acquisition Acquires MODA Technology Partners.
- Acquisition Acquires Lonza.
- Funding First funding round of $18.0M.
- Acquisition Acquires Zelam.
- Acquisition Acquires Triangle Research Labs.
- Acquisition Acquires InterHealth Nutraceuticals.
- Acquisition Acquires Capsugel.
- Acquisition Acquires PharmaCell.
- Acquisition Acquires Micromacinazione.
- Acquisition Acquires Octane.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Synaffix.
- Funding Latest funding round, Seed, of $100K.
- Exit Acquired by SBI Mutual Fund.
Web traffic of Lonza
The website of Lonza (lonza.com) receives about 296.7K visits a month and ranks #94,343 among all websites worldwide, #648 in Chemical Industry.
- Monthly visits296.7K
▼ 7.4% vs previous month
- Unique visitors141.6K
per month
- Global rank#94,343
among all websites
- Category rank#648
Heavy Industry and Engineering · Chemical Industry
- Bounce rate47%
- Pages per visit7.1
- Average visit1 min 03 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Lonza. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stepan.com | 100% | 50.9K | #598,952 | View details | |
| tetratec.com | 90% | View details | |||
| dynalene.com | 75% | 15.8K | #1,745,143 | View details | |
bkw.ch | bkw.ch | 51% | #276,024 | – | |
| ionbond.com | 51% | 25K | #1,091,262 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Lonza
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lonza
Complete news archive for Lonza
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lonza
Lonza was founded in 1897 and raised its 1st funding round 113 years after it was founded.
Lonza is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Pierre Alain Ruffieux is the CEO of Lonza, as recorded in our data.
Lonza is a funded company, having raised a total of $100K across 6 funding rounds to date. The company's 1st funding round was a Grant of $18M, raised on Nov 2010.
Lonza has 18,690 employees.
Annual revenue of Lonza is $8.24B as on Dec 31, 2025.
Provider of CDMO services to pharma, biotech, and specialty ingredient markets. The company offers a complete range of development and manufacturing services for fine chemicals, advanced intermediates, active pharmaceutical ingredients (APIs), biologics, and functional ingredients. They claim to offer synergies between chemical synthesis and biotechnology to enable the production of tailor-made intermediates and APIs for use as pharmaceuticals, biotherapies, nutraceuticals, and cosmetics. Their proprietary platforms and development technologies such as GS Gene enable them to offer customized biological and chemical manufacturing solutions. In 2022, the company recorded annual revenues of 6.52B and a net profit of 1.27B.
Lonza offers Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
Yes, Lonza is publicly traded on SIX under the ticker symbol LONN.
Lonza has made 10 acquisitions, including Capsugel, InterHealth Nutraceuticals, and Lonza.
Lonza has 5 investors. Key investors include SBI Mutual Fund, European Union, ALSA Ventures, U.S. Department of Defense, and Upekkha.
Lonza is associated with 3 legal entities: Capsugel Healthcare Private Limited, Arch Protection Chemicals Private Limited, Lonza India Private Limited.